Skip to main content
SpringerLink
Log in

Autoantibody Profile in Systemic Sclerosis as a Marker for Esophageal and Other Organ Involvement in Turkish Populations

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Systemic sclerosis (SSc) is a connective tissue disorder of unknown etiology characterized by fibrosis and vascular obliteration in the skin, gastrointestinal tract, lungs, and heart. Our aim was to investigate the autoantibody profile in patients with esophageal involvement of SSc and to describe the relationship between the autoantibody profile and organ involvement in SSc. We studied 47 SSc patients, all with esophageal involvement shown on esophageal manometry. The patients were separated into three groups based on the absence or presence of ANA, Scl70, and ACA. In this study ANA and Scl70 were present more frequently than ACA in patients with esophageal involvement of SSc. Pulmonary involvement and heart involvement were seen more in Scl70-positive and ACA-positive patients, respectively. We conclude that in patients with SSc, closer follow-up with autoantibody profile may enable early diagnosis of specific organ involvement and treatment of debilitating symptoms, with avoidance of potential life-threatening complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43(11):2437–2444

    Article  PubMed  CAS  Google Scholar 

  2. Sallam H, Mcnearney TA, Chen JDZ (2006) Systematic review:pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis. Aliment Pharmacol Ther 23:691–712

    Article  PubMed  CAS  Google Scholar 

  3. Ehrmann S (1903) Ueber die Bieziehung der Sklerodermie Zu den Autotoxichen erythemen. Ubien Med Wschr 53:1097–1159

    Google Scholar 

  4. Ebert EC (2006) Esophageal disease in scleroderma. J Clin Gastroenterol 40:769–775

    Article  PubMed  Google Scholar 

  5. Poirier TJ, Rankin GB (1972) Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol 58:30–44

    PubMed  CAS  Google Scholar 

  6. Rose S, Young MA, Reynolds JC (1998) Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 27(3):563–594

    Article  PubMed  CAS  Google Scholar 

  7. Cohen S (1979) Motor disorders of the esophagus. N Engl J Med 301(4):184–192

    Article  PubMed  CAS  Google Scholar 

  8. Lock G, Pfeifer M, Straub RH, Zeuner M, Lang B, Schölmerich J, Holstege A (1998) Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 93:341–345

    Article  PubMed  CAS  Google Scholar 

  9. Ferri C, Giuggioli D, Sebastiani M, Colaci M, Emdin M (2005) Heart involvement and systemic sclerosis. Lupus 14:702–707

    Article  PubMed  CAS  Google Scholar 

  10. Gonzalez R, Storr M, Bloching H, Seige M, Ott R, Allescher HD (2001) Autoantibody profile in progressive systemic sclerosis as markers for esophageal involvement. J Clin Gastroenterol 32(2):123–127

    Article  PubMed  CAS  Google Scholar 

  11. Preliminary criteria for the classification of systemic sclerosis. Subcommittee for scleroderma criteria of the American Rheumatism Association. Arthritis Rheum 23:581–590

    Article  Google Scholar 

  12. Richter JE, Wu WC, Johns DN, Blackwell JN, Nelson JL 3rd, Castell JA, Castell DO (1987) Esohageal manometry in 95 healthy adult volunteers Variability of pressures with age and frequency ob ‘abnormal’ contractions. Dig Dis Sci 32:583–592

    Article  PubMed  CAS  Google Scholar 

  13. Paolo A, Casa DD, Danieli E, Missale G, Cattaneo R, Cestari R (2005) Oesophageal manometry in early and definite systemic sclerosis. Clin Rheumatol 24:370–376

    Article  Google Scholar 

  14. Murata I, Takenaka K, Yoshinoya S, Kikuchi K, Kiuchi T, Tanigawa T, Ito K (1997) Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. Chest 111:36–43

    PubMed  CAS  Google Scholar 

  15. Ferri C, Valentini G, Cozzi F, et al. (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 81:139–153

    Article  PubMed  Google Scholar 

  16. Catoggio LJ, Bernstein RM, Black CM, Hughes GRV, Maddison PJ (1983) Serological markers in progressive systemic sclerosis:clinical correlations. Ann-Rheum Dis 42(1):23–27

    Article  PubMed  CAS  Google Scholar 

  17. Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie W, Cooper B, Laing TJ, Schottenfeld D (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arth Rheum 48(8):2246–2255

    Article  Google Scholar 

  18. Furst DE, Clements PJ, Wong WK, Mayes MD, Wigley F, White B, Weisman M, Barr W, Moreland L, Martin R, Medsger TA, Steen V, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Peter JB, Seibold JR (2001) Effects of American college of rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. Rheumatology 40(6):615–622

    Article  PubMed  CAS  Google Scholar 

  19. Marie I, Dominique S, Levesque H, Ducrotte P, Denıs P, Hellot MF, Courtois H (2001) Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arth Rheum 45:346–354

    Article  CAS  Google Scholar 

  20. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich AB, Medsger TA, Lucas M, Michet CJ, Kuwana M, Yasuaka H, Hoogen F, Boome L, Laar JM, Verbeet NL, Matucci-Cerinic M, Georgountzos A, Moutsopoulos HM. Mortality in systemic sclerosis:an international meta-analysis of individual patient data. Am J Med 118:2–10

    Article  PubMed  Google Scholar 

  21. Bryan C, Knight C, Black CM, Silman AJ (1999) Prediction of five-year survival following presentation with scleroderma:development of a simple model using using three disease factors at first visit. Arth Rheum 42:2660–2665

    Article  CAS  Google Scholar 

  22. Miller MH, Littlejohn GO, Davidson A, Jones B, Topliss DJ (1987) The clinical significance of the anticentromere antibody. Br J Rheumatol 26:17–21

    Article  PubMed  CAS  Google Scholar 

  23. Yarze JC, Varga J, Stampfl D, Castell DO, Jimenez SA (1993) Esophageal function in systemic sclerosis:A prospective evaluation of motility and acid reflux in 36 patients. Am J Gastroenterol 88(6):870–876

    PubMed  CAS  Google Scholar 

  24. Steen VD, Ziegler GL, Rodnan GP, Medsger TA (1984) Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arth Rheum 27(2):125–131

    Article  CAS  Google Scholar 

  25. Kallenberg CG, Pastoor GW, Wouda AA, The TH (1982) Antinuclear antibodies in patients with Raynoud's phenomenon:clinical significance of anticentromer antibodies. Ann Rheum Dis 41:382–387

    PubMed  CAS  Google Scholar 

  26. Fritzler MJ, Kinsella TD (1980) The CREST syndrome a distinct serologic entitity with anticentromere antibodies. Am J Med 69:520–526

    Article  PubMed  CAS  Google Scholar 

  27. McCarty GA, Rice JR, Bembe ML, Barada FA Jr (1983) Anticentromere antibody. Clinical correlations and association with favorable prognosis in patients with scleroderma variants. Arth Rheum 26:1–7

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Baskent University Faculty of Medicine, Ankara, Turkey

    Nurten Savas

  2. Department of Gastroenterology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey

    Ulku Dagli, Sedef Kuran & Burhan Sahin

  3. Department of Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey

    Esin Ertugrul

  4. Baskent University, Department of Gastroenterology, Fevzi Cakmak Cad, 10.Sok, No: 45 Bahcelievler, Ankara, Turkey

    Nurten Savas

Authors
  1. Nurten Savas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulku Dagli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Esin Ertugrul
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sedef Kuran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Burhan Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nurten Savas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Savas, N., Dagli, U., Ertugrul, E. et al. Autoantibody Profile in Systemic Sclerosis as a Marker for Esophageal and Other Organ Involvement in Turkish Populations. Dig Dis Sci 52, 3081–3086 (2007). https://doi.org/10.1007/s10620-007-9809-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-007-9809-1

Keywords

Search

Navigation